| Secretin-activated brown fat mediates prandial thermogenesis to induce satiation Y Li, K Schnabl, SM Gabler, M Willershäuser, J Reber, A Karlas, S Laurila, ... Cell 175 (6), 1561-1574. e12, 2018 | 230 | 2018 |
| Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a … J Oldgren, S Laurila, A Åkerblom, A Latva‐Rasku, E Rebelos, H Isackson, ... Diabetes, Obesity and Metabolism 23 (7), 1505-1517, 2021 | 61 | 2021 |
| Secretin activates brown fat and induces satiation S Laurila, L Sun, M Lahesmaa, K Schnabl, K Laitinen, R Klén, Y Li, ... Nature metabolism 3 (6), 798-809, 2021 | 58 | 2021 |
| Both sedentary time and physical activity are associated with cardiometabolic health in overweight adults in a 1 month accelerometer measurement T Sjöros, H Vähä-Ypyä, S Laine, T Garthwaite, M Lahesmaa, SM Laurila, ... Scientific reports 10 (1), 20578, 2020 | 49 | 2020 |
| Circulating neurofilament is linked with morbid obesity, renal function, and brain density E Rebelos, E Rissanen, M Bucci, O Jääskeläinen, MJ Honka, ... Scientific reports 12 (1), 7841, 2022 | 40 | 2022 |
| u Din M, Bast-Habersbrunner A, Virtanen KA, Fromme T, Bolze F, O’Farrell LS, Alsina-Fernandez J, Coskun T, Ntziachristos V, Nuutila P, Klingenspor M Y Li, K Schnabl, SM Gabler, M Willershäuser, J Reber, A Karlas, S Laurila, ... Secretin-activated brown fat mediates prandial thermogenesis to induce …, 2018 | 14 | 2018 |
| Secretin modulates appetite via brown adipose tissue-brain axis L Sun, S Laurila, M Lahesmaa, E Rebelos, KA Virtanen, K Schnabl, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (6), 1597-1606, 2023 | 12 | 2023 |
| [11C]carfentanil PET imaging for studying the peripheral opioid system in vivo: effect of photoperiod on mu-opioid receptor availability in brown adipose tissue L Sun, R Aarnio, EA Herre, S Kärnä, S Palani, H Virtanen, H Liljenbäck, ... European Journal of Nuclear Medicine and Molecular Imaging 50 (2), 266-274, 2023 | 9 | 2023 |
| The utilization of positron emission tomography in the evaluation of renal health and disease KA Amoabeng, S Laurila, LE Juárez-Orozco, ABL Marthinsen, ... Clinical and Translational Imaging, 1-11, 2022 | 9 | 2022 |
| Pleiotropic effects of secretin: a potential drug candidate in the treatment of obesity? S Laurila, E Rebelos, MJ Honka, P Nuutila Frontiers in Endocrinology 12, 737686, 2021 | 8 | 2021 |
| Short‐term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A … SV Nesterov, J Räty, W Nammas, T Maaniitty, X Galloo, J Stassen, ... European Journal of Heart Failure 26 (1), 117-126, 2024 | 5 | 2024 |
| Novel effects of the gastrointestinal hormone secretin on cardiac metabolism and renal function S Laurila, E Rebelos, M Lahesmaa, L Sun, K Schnabl, TM Peltomaa, ... American Journal of Physiology-Endocrinology and Metabolism 322 (1), E54-E62, 2022 | 5 | 2022 |
| Insulin-stimulated brain glucose uptake correlates with brain metabolites in severe obesity: A combined neuroimaging study E Rebelos, A Latva-Rasku, K Koskensalo, L Pekkarinen, E Saukko, ... Journal of Cerebral Blood Flow & Metabolism 44 (3), 407-418, 2024 | 4 | 2024 |
| Renal cortical glucose uptake is decreased in insulin resistance and correlates inversely with serum free-fatty acids E Rebelos, A Mari, MJ Honka, L Pekkarinen, A Latva-Rasku, S Laurila, ... The Journal of Clinical Endocrinology & Metabolism 109 (4), 1033-1040, 2024 | 3 | 2024 |
| Ruskean rasvakudoksen toiminta ja merkitys S Laurila, M Lahesmaa, P Nuutila, KA Virtanen Suomalainen lääkäriseura Duodecim, 2020 | 3 | 2020 |
| Secretin activates brown fat and induces satiation in humans S Laurila, M Lahesmaa, L Sun, K Braun, K Virtanen, K Laitinen, ... Diabetologia 61, S70-S71, 2018 | 3 | 2018 |
| Brown adipose tissue fat-fraction is associated with skeletal muscle adiposity M Ogawa, K Koskensalo, S Laurila, M Holstila, M Lahesmaa, KA Virtanen, ... European journal of applied physiology, 1-10, 2022 | 2 | 2022 |
| Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on myocardial function and metabolism in type 2 diabetes patients: a randomized … J Oldgren, S Laurila, A Åkerblom, A Latva-Rasku, E Rebelos, H Isackson, ... Journal of the American College of Cardiology 75 (11_Supplement_1), 1610-1610, 2020 | 2 | 2020 |
| SGLT2 inhibitor Dapagliflozin increases skeletal muscle and brain fatty acid uptake in individuals with type 2 diabetes: a randomized double-blind placebo-controlled positron … A Latva-Rasku, E Rebelos, J Tuisku, R Aarnio, A Bhowmik, H Keskinen, ... Diabetes Care 47 (9), 1630-1637, 2024 | 1 | 2024 |
| Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes J Oldgren, S Laurila, A Akerblom, A Latva-Rasku, E Rebelos, H Isackson, ... Diabetologia 63 (SUPPL 1), S62-S63, 2020 | 1 | 2020 |
